Home » ocular neovascularization

Iris Pharma is a world-class ocular specialist R&D company, with a department of basic research fully dedicated to the development of new ocular neovascularization and new microsurgical procedure in the animal eye. Today, Iris Pharma provides ophthalmology services of 23 validated different animal models, like Choroidal neovascularization (CNV) or ocular neovascularization.

Evaluation of the test compound's efficacy in multiple models of ocular neovascularization

Our basic Research Department creates and validates novel in vivo model for the evaluation of the efficacy of drugs in the ocular neovascularization.

Recently, the Iris Pharma Research Team has validated several animal models to investigate the various aspects of retinal degenerescence and ocular neovascularization: retinopathy of prematurity (ROP, hyperoxia model in pup mice), chemical burn (alcohol, sodium hydroxyde models in rats, mice and rabbits), retinal vascular permeability (VEGF-induced leakage) in rabbits, and choroidal ocular neovascularization model (CNV) in rats using argon laser.

Iris Pharma offers accurate ocular neovascularization studies

The merger of Iris Pharma with Clirophtha offers to this ophthalmology CRO privileged and well-established relationship with leading professors in the fields of ophthalmology, pharmacokinetic studies, ocular neovascularization studies etc.